Genetics Institute, Inc.

Wyeth

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Other

The Johns Hopkins University

Harvard College

Medimmune Limited

Cambridge Antibody Technology Limited

The Government of the United States of America

Matthew James Whitters

Mary Collins

Debra D Donaldson

Clive R Wood

Lori J Fitz

Tamlyn Neben

Deborah A Young

Joann Witek

Beatriz M Carreno

Viia Valge-Archer

Andrew James Williams

Laura L Carter

Michelle J Unger

Michael J Grusby

Marsha Wills-Karp

Thomas A Wynn

Monica G Chiaramonte

Andrea Wurster

Glenn R Larsen

Marion T Kasaian

Ethan Shevach

Michael Chapman Byrne

Lesile D Lowe

Rebecca Suzanne McHugh

Margery Ma

Kyri Dunussi

Leslie D Lowe

Geoffrey Laurence Stephens

Padmalatha S Reddy

Lori Fitz

Joann S Witek

Michelle Ungar

Beatriz Carreno

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.

[object Object]

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding

The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.

Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies

The present invention is directed to methods for treating asthma.

Method and compositions for treating asthma

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.

Cytokine receptor chain

Antibodies against human or mouse IL-21 receptor

Methods and compositions for modulating T helper (Th) cell development and function

Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.

Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

Methods and compositions for modulating interleukin-21 receptor activity

Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.

Methods of treatment with antagonists of MU-1

Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding

IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

IL-13 Receptor chain

IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.

Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor

Growing community of inventors

Hudson, MA, United States of America

Matthew James Whitters